Statistiques de base
| LEI | 391200D6GFSVFGFQTL13 |
| CIK | 1712641 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biofrontera AG - ADR
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| March 10, 2022 |
Exhibit 99.1 News release Biofrontera files Form 15F to suspend SEC Reporting Requirements and starts trading Level I ADS program on US OTC market Leverkusen, Germany, March 09, 2022 ? Biofrontera AG (Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today the voluntary filing of Form 15F with the United States Securities and Exchange Commission (SEC) to termina |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 9, 2022 |
As filed with the Securities and Exchange Commission on March 9, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2022 |
As filed with the United States Securities and Exchange Commission on March 9, 2022 Registration No. |
|
| March 9, 2022 |
As Filed With the Securities and Exchange Commission on March 9, 2022 As Filed With the Securities and Exchange Commission on March 9, 2022 Registration No. |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 16)* Biofrontera AG (Name of Issuer) Ordinary Shares, nominal value ?1.00 per share (including Ordinary Shares represented by American Depository Shares (ADSs) at a ratio of two Ordinary Shares per ADS) (Title of Class of Securities) 09075G105 ** (CUSIP Numb |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38396 BIOFRONTERA AG, NASDAQ Capital Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Hemmelrather Weg |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 24, 2022 |
Exhibit 99.1 Ad hoc release Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG: Management Board and supervisory board are going to submit proposals for resolutions on capital measures at an extraordinary shareholders? meeting Leverkusen, Germany, February 24, 2022 ? The management board and supervisory board resolved today to submit resolution proposals for capital measures at an extraordinary |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 22, 2022 |
Exhibit 99.1 Ad hoc release Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG: Changes in the supervisory board Leverkusen, Germany, February 22, 2022 ? Biofrontera AG (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), announces that Prof. Dr. Franca Ruhwedel today resigned from her position as a member of the supervisory board with immediate effect for good cause. Prof. Dr. Ruhwedel was nominated |
|
| February 14, 2022 |
Exhibit 99.1 Ad hoc release Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs Leverkusen, Germany, February 14, 2022 ? Biofrontera AG (the ?Company?) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (?ADS?) should be delisted from the Nasdaq Ca |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 10, 2022 |
BFRI / Biofrontera Inc / Biofrontera AG Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biofrontera Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09077D 100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 1, 2022 |
Biofrontera AG announces progress of phase III study for the treatment of sBCC with Ameluz® Exhibit 99.1 News release Biofrontera AG announces progress of phase III study for the treatment of sBCC with Ameluz® Leverkusen, Germany, February 1, 2021 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, is making progress in patient recruitment of its US phase III clinical study to investigate the treatment of superficial |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| January 13, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germa |
|
| January 13, 2022 |
Exhibit 99.1 Ad hoc release Ad-hoc Release pursuant to Art. 17 MAR Biofrontera announces preliminary revenue figures for the full year 2021 Leverkusen, Germany, January 13, 2022 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2021 as well as the fourth quarter |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| December 29, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG announces reduction of shareholding in Biofrontera Inc. below 50% Leverkusen, Germany, December 29, 2021 - Today, Biofrontera AG (ISIN: DE0006046113), was informed by Biofrontera Inc. (Nasdaq: BFRI) that the total amount of BFRI shares outstanding has increased due to exercises of previously iss |
|
| December 21, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements, The undersigned acknowledge that each shall be |
|
| December 21, 2021 |
Exhibit 99.4 Agreement About the Settlement of Litigations among 1. Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, 2. Mr. Wilhelm K. T. Zours, business adress: Deutsche Balaton AG, Ziegelh?user Landstra?e 1, 69120 Heidelberg 3. Deutsche Balaton AG, Ziegelh?user Landstra?e 1, 69120 Heidelberg 4. Delphi Unternehmensberatung AG, Ziegelh?user Landstra?e 1, 69120 Heidelberg 5. VV Beteiligungen |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* Biofrontera AG (Name of Issuer) Ordinary Shares, nominal value €1.00 per share (including Ordinary Shares represented by American Depository Shares (ADSs) at a ratio of two Ordinary Shares per ADS) (Title of Class of Securities) 09075G105 ** (CUSIP Numb |
|
| December 14, 2021 |
Exhibit 99.1 Annual General Meeting Biofrontera Aktiengesellschaft December 14, 2021, 11:00 AM Voting results: Agenda Items Number of Shares with Valid Votes % of Registered Share Capital Votes for % Votes For Votes Against % Votes Against Proposed Decision 2 Resolution concerning the discharge of the members of the Management Board for the 2020 financial year 35,567,873 62.71 16,997,765 47.7897 1 |
|
| December 14, 2021 |
Biofrontera AG announces results of the elections for the new Supervisory Board Exhibit 99.2 News release Biofrontera AG announces results of the elections for the new Supervisory Board Leverkusen, Germany, December 14, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announces the results of the election to the new Supervisory Board at the Annual General Meeting on December 14, 2021. The shareholders present rep |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| December 13, 2021 |
Exhibit 99.1 News release Biofrontera enrolls first patient to phase IIb clinical study evaluating Ameluz? / BF-RhodoLED? for moderate to severe acne Leverkusen, Germany, December 13, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, is pleased to announce that it has commenced patient enrollment to its phase IIb study |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| December 8, 2021 |
Biofrontera AG obtains notice of allowance for US patent on PDT-lamp and treatment method Exhibit 99.1 News release Biofrontera AG obtains notice of allowance for US patent on PDT-lamp and treatment method Leverkusen, Germany, December 8, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announces that its wholly owned subsidiary Biofrontera Pharma GmbH has received a notice of allowance from the United States Patent and Tr |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| December 2, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG announces timing of the departure of the CEO Leverkusen, Germany, December 2, 2021 - Biofrontera AG (ISIN: DE0006046113) (the ?Company?) has announced on November 10, 2021, that Prof. Dr. L?bbert has resigned from his position as member of the Management Board effective at the end of May 2022 an |
|
| December 2, 2021 |
Biofrontera obtains notice of allowance for US patent on innovative illumination protocol Exhibit 99.1 News release Biofrontera obtains notice of allowance for US patent on innovative illumination protocol Leverkusen, Germany, December 2, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, announces that its wholly owned subsidiary Biofrontera Pharma GmbH has received a notice of allowance from the United Stat |
|
| December 2, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG: Biofrontera Inc. announces closing of USD15 million private placement Leverkusen, Germany, December 1, 2021 - On November 29, 2021, Biofrontera AG (ISIN: DE0006046113) announced that its US subsidiary Biofrontera Inc. had entered into a private placement in the amount of USD 15 million (gross p |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 30, 2021 |
Exhibit 99.1 Biofrontera Aktiengesellschaft Leverkusen - ISIN: DE0006046113 / WKN: 604611 - Addition to the agenda of the Annual General Meeting on 14 December 2021 pursuant to section 122 (2) AktG at the request of a shareholder The Annual General Meeting of Biofrontera AG was convened for Tuesday, 14 December 2021, with agenda items 1 to 7 as a virtual Annual General Meeting, i.e. without the ph |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 29, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG: Biofrontera Inc. announces USD 15 million private placement Leverkusen, Germany, November 29, 2021 - Biofrontera AG announces that its US subsidiary Biofrontera Inc. has entered into a private placement in the amount of USD 15 million (gross proceeds). Biofrontera Inc. will issue 2,875,143 comm |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* Biofrontera AG (Name of Issuer) Ordinary Shares, nominal value ?1.00 per share (including Ordinary Shares represented by American Depository Shares (ADSs) at a ratio of two Ordinary Shares per ADS) (Title of Class of Securities) 09075G105 ** (CUSIP Numb |
|
| November 29, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera reaches out-of-court settlement with DUSA Pharmaceuticals, Inc. Leverkusen, Germany, November 29, 2021 - Biofrontera AG (ISIN: DE0006046113) (the ?Company?) with its wholly owned German subsidiaries, and Biofrontera Inc. (Nasdaq: BFRI), a U.S. subsidiary of the Company, in which it holds less than |
|
| November 29, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements, The undersigned acknowledge that each shall be |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 29, 2021 |
Exhibit 99.4 [***] indicates material has been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission. A complete copy of this agreement has been filed separately with the Securities and Exchange Commission. Agreement About the Settlement of Litigations among 1. Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, 2. Mr. Wilhelm K. T. Zours, busin |
|
| November 24, 2021 |
Exhibit 99.2 Information pursuant to Section 125 Para. 5 of the German Stock Corporation Act (AktG) in conjunction with Art. 4 Para. 1 and Table 3 of the Annex to Implementing Regulation (EU) 2018/1212 Type of information Description A. Specification of the message 1. Unique identifier of the event BFAOHV211214 2. Type of message Meeting Notice in the format pursuant to the Implementing Regulation |
|
| November 24, 2021 |
Exhibit 99.1 Biofrontera Aktiengesellschaft, Leverkusen, Germany - ISIN: DE0006046113 / WKN: 604611 - Invitation to the Annual General Meeting We hereby invite our shareholders to attend the Annual General Meeting of Shareholders to be held at 11:00 a.m. on Tuesday, December 14, 2021. (virtual) Annual General Meeting. The Annual General Meeting will be held without the physical presence of the sha |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 19, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG announces mediation results Leverkusen, Germany, November 19, 2021 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 18, 2021 |
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021 Exhibit 99.2 News release Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021 Leverkusen, Germany, November 17, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and b |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 18, 2021 |
Exhibit 99.1 Quarterly report Q3 2021 Dear shareholders, In recent weeks, there have been many upheavals at Biofrontera, which also affect me personally and which I would like to explain to you, dear shareholders, as some of you have been ?long-standing companions? of Biofrontera. For this reason, I would like to take this opportunity to provide you with a more detailed explanation of the decision |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 16, 2021 |
Biofrontera AG announces initiation of clinical studies Exhibit 99.1 News release Biofrontera AG announces initiation of clinical studies Leverkusen, Germany, November 16, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, announces that two clinical studies for its prescription drug Ameluz? in the United States are being started with site initiations currently in progress, s |
|
| November 10, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR CEO seeks early retirement from the Management Board Leverkusen, November 10, 2021 - Prof. Hermann L?bbert, CEO of Biofrontera AG (ISIN: DE0006046113), has informed the Supervisory Board today that he intends to leave the Management Board of Biofrontera AG prematurely. Prof. L?bbert had been appointed as a mem |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 9, 2021 |
Exhibit 99.1 News release Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021 Leverkusen, Germany, November 09, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wedne |
|
| November 3, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Early repayment of EIB loan Leverkusen, November 03, 2021 - Biofrontera AG (ISIN: DE0006046113) today decided to prematurely repay the loan raised from the European Investment Bank (?EIB?). Biofrontera AG previously announced that its US subsidiary Biofrontera Inc. had completed a successful capital raise by w |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 2, 2021 |
Exhibit 99.1 News release Biofrontera is setting the path for further expansion in the world?s largest pharmaceutical market with the IPO of its US subsidiary Biofrontera Inc. Leverkusen, Germany, November 02, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) Biofrontera AG (ISIN: DE0006046113) has today announced the closing of the successful IPO of its US subsidiary Biofrontera |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 2, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera Inc. closes IPO Leverkusen, Germany, November 02, 2021 ? On July 6, 2021, Biofrontera AG announced that Biofrontera Inc. intends to raise capital by means of an initial public offering and a stock exchange listing in the United States (?IPO?). Reference is made to the further announcements dated Oc |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| October 29, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Initial public offering price of Biofrontera Inc. IPO Leverkusen, Germany, October 29, 2021 ? On July 6, 2021, Biofrontera AG announced that its US-subsidiary Biofrontera Inc. intends to raise capital by means of an initial public offering and a stock exchange listing in the United States (?IPO?). On October 2 |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| October 28, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG approves modification of the US-IPO of Biofrontera Inc. Leverkusen, Germany, October 27, 2021 ? On July 6, 2021, Biofrontera AG announced that its US-subsidiary Biofrontera Inc. intends to raise capital by means of an initial public offering and a stock exchange listing in the United States (?IP |
|
| October 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| October 22, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG receives FDA-approval of the BF-RhodoLED? XL lamp Leverkusen, Germany, October 22, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today announced the approval of the new red-light source for photodynamic therapy (P |
|
| October 1, 2021 |
Biofrontera reports preliminary approximate revenues for the month of September 2021 Exhibit 99.1 News release Biofrontera reports preliminary approximate revenues for the month of September 2021 Leverkusen, Germany, October 01, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021. The Company?s preliminary, unaudited revenue fro |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| October 1, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG approves IPO of Biofrontera Inc. in the USA Leverkusen, Germany, October 1, 2021 ? Biofrontera AG currently holds a 100 % stake in the US-based subsidiary Biofrontera Inc. On July 6, 2021, Biofrontera AG published an insider information pursuant to Article 17 MAR announcing that Biofrontera Inc. |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| September 8, 2021 |
Biofrontera reports preliminary revenue for the month of August 2021 Exhibit 99.1 News release Biofrontera reports preliminary revenue for the month of August 2021 Leverkusen, Germany, September 8, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021. The Company?s preliminary, unaudited revenue from product sales in |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of p |
|
| August 19, 2021 |
Exhibit 99.1 News release Biofrontera reports financial results for the six months ended June 30, 2021 Leverkusen, Germany, August 19, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021. Key financial figures and business performance for the six |
|
| August 19, 2021 |
Exhibit 99.2 Year-to-date highlights 2021 ? Increase in product revenue by 35% in the first half of 2021 compared with the same period of the previous year ? Strong recovery in sales performance since mid-March 2021, with Q2 2021 sales exceeding those of 2019, prior to the onset of pandemic-related sales decline in 2020. ? Completion of the capital increase in February 2021 with gross proceeds of |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 16, 2021 |
Biofrontera AG: Pre-announcement of a financial report according to articles 114 - 117 WpHG Exhibit 99.1 Biofrontera AG: Pre-announcement of a financial report according to articles 114 - 117 WpHG Pre-announcement of a financial report according to articles 114 - 117 WpHG Leverkusen, Germany (pta010/02.08.2021/09:00) - Biofrontera AG announces that the following financial reports shall be disclosed: report: half-year report of the group 2021 reporting period: 01.01.2021 - 30.06.2021 web |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 12, 2021 |
Exhibit 99.1 News release Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021 Leverkusen, Germany, August 12, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19 |
|
| August 9, 2021 |
Biofrontera reports preliminary revenue for the month of July 2021 Exhibit 99.1 News release Biofrontera reports preliminary revenue for the month of July 2021 Leverkusen, Germany, August 9, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of July 2021. The Company?s preliminary, unaudited revenue from product sales in July 2 |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princi |
|
| July 7, 2021 |
Publication of inside information pursuant to Article 17 MAR Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera Inc. seeks IPO in the USA Leverkusen, Germany, July 6, 2021 ? Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc. Biofrontera AG had already announced that opportunities for capital raises were being evaluated including a potential initial public offering (?IPO?) of |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princi |
|
| July 6, 2021 |
Biofrontera reports preliminary revenue for the month of June 2021 Exhibit 99.1 News release Biofrontera reports preliminary revenue for the month of June 2021 Leverkusen, Germany, July 6, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021. The Company?s preliminary, unaudited revenue from product sales in June 202 |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princi |
|
| July 2, 2021 |
Exhibit 99.1 Biofrontera AG: Correction of a Release according to Article 40, Section 1 of the WpHG from 23.06.2021 Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta034/01.07.2021/16:00) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Po |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princi |
|
| June 23, 2021 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/23.06.2021/19:30) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princi |
|
| June 22, 2021 |
Biofrontera provides update on clinical developments Exhibit 99.1 Biofrontera provides update on clinical developments Leverkusen, Germany, June 22, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today provides an update on its clinical developments. In February and March 2021, the Company announced two submissions to the U.S. Food and Drug Administration (FDA), enabli |
|
| June 7, 2021 |
Biofrontera reports preliminary revenue for the month of May 2021 Exhibit 99.1 News release Biofrontera reports preliminary revenue for the month of May 2021 Leverkusen, Germany, June 7, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021. The Company?s preliminary, unaudited revenue from product sales in May 2021 a |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princi |
|
| May 11, 2021 |
Biofrontera reports Q1 2021 financial results Exhibit 99.2 Biofrontera reports Q1 2021 financial results Leverkusen, Germany, May 11, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Q1 2021 key financial figures and business performance In EUR thousands 3M 2021 3M 2020 Change Revenue |
|
| May 11, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princip |
|
| May 11, 2021 |
Summary of the business performance in the first quarter 2021 Exhibit 99.1 Summary of the business performance in the first quarter 2021 Following initial pandemic-related an initial, pandemic-related slow start at the beginning of the year, Biofrontera?s business development in the first months of the year has been encouragingly positive since mid-March. As expected, business activities and consequently sales continue to be strongly dependent on the develop |
|
| May 6, 2021 |
Biofrontera reports preliminary revenue for the month of April 2021 Exhibit 99.1 News release Biofrontera reports preliminary revenue for the month of April 2021 Leverkusen, May 6, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021. The Company?s preliminary, unaudited revenue from product sales in April 2021 amoun |
|
| May 6, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princip |
|
| May 3, 2021 |
Biofrontera AG: First quarter conference call to be held on May 12, 2021 Exhibit 99.1 News release Biofrontera AG: First quarter conference call to be held on May 12, 2021 Leverkusen, Germany, May 3, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, will be releasing its financial results for the first quarter 2021 on Tuesday, May 11, 2021. Conference calls for shareholders and interested in |
|
| May 3, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princip |
|
| April 12, 2021 |
Exhibit 12.1 CERTIFICATION I, Hermann L?bbert, certify that: 1. I have reviewed this annual report on Form 20-F of Biofrontera AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to th |
|
| April 12, 2021 |
Articles of Association of Biofrontera AG Exhibit 1.1 CONVENIENCE TRANSLATION Articles of Association Biofrontera AG I. General Provisions ? 1 Company Name The name of the Company is: Biofrontera AG ? 2 Registered Office The registered office of the Company is Leverkusen. ? 3 Purpose of the Company (1) The purpose of the Company is the research, development and distribution of pharmaceuticals, as well as the assumption of the position of |
|
| April 12, 2021 |
Consent of Warth & Klein Grant Thornton AG Exhibit 15.1 Warth & Klein Grant Thornton AG | Postfach 30 10 24 | 40410 D?sseldorf Biofrontera AG Herrn Ludwig Lutter Chief Financial Officer Hemmelrather Weg 201 53177 Leverkusen Warth & Klein Grant Thornton AG Wirtschaftspr?fungsgesellschaft Johannstra?e 39 40476 D?sseldorf T +49 211 9524 - 0 E [email protected] W https://www.wkgt.com/en CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FI |
|
| April 12, 2021 |
Exhibit 2.5 DESCRIPTION OF SECURITIES Description of Share Capital and Articles of Association The following description is a summary of certain information relating to Biofrontera AG?s share capital, as well as certain provisions of our articles of association and the German Stock Corporation Act. Unless stated otherwise, the description insofar as it relates to our articles of association is bas |
|
| April 12, 2021 |
Biofrontera AG Annual report 2020 Exhibit 99.2 |
|
| April 12, 2021 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with Biofrontera AG?s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the ?Exchange Act?) and Section 1350 of Chapter 63 of Title 18 of the United States Code. H |
|
| April 12, 2021 |
Biofrontera reports results for the 2020 financial year Exhibit 99.1 News release Biofrontera reports results for the 2020 financial year Leverkusen, Germany, April 12, 2021 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its consolidated results for the fiscal year ended December 31, 2020. At the same time, the Company provided an overview of current operational |
|
| April 12, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) [ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI |
|
| April 12, 2021 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with Biofrontera AG?s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the ?Exchange Act?) and Section 1350 of Chapter 63 of Title 18 of the United States Code. L |
|
| April 12, 2021 |
Exhibit 12.2 CERTIFICATION I, Ludwig Lutter, certify that: 1. I have reviewed this annual report on Form 20-F of Biofrontera AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the |
|
| April 12, 2021 |
Employment Agreement – Hermann Lübbert (English Translation) Exhibit 4.6 CONVENIENCE TRANSLATION. The German version is authoritative. Service Agreement between Biofrontera Aktiengesellschaft, Hemmelrather Weg 201, 51377 Leverkusen, represented by the Supervisory Board through its Chairman Dr. Ulrich Granzer, - hereinafter referred to as the ?Company? - and Prof. Dr. Hermann L?bbert, H?henstra?e 59, 51381 Leverkusen, -hereinafter referred to as the ?Managem |
|
| April 8, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| April 8, 2021 |
Biofrontera announces preliminary revenue for Q1 2021 Exhibit 99.1 News release Biofrontera announces preliminary revenue for Q1 2021 Leverkusen, Germany, April 08, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the first quarter 2021. The Company?s preliminary unaudited revenue for the period January 1 to March 31, 2021 |
|
| April 1, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| April 1, 2021 |
Biofrontera AG: Pre-announcement of a financial report according to articles 114 - 117 WpHG Exhibit 99.1 Biofrontera AG: Pre-announcement of a financial report according to articles 114 - 117 WpHG Leverkusen (pta/31.03.2021/14:00) - Biofrontera AG announces that the following financial reports shall be disclosed: report: year report of the group 2020 reporting period: 01.01.2020 - 31.12.2020 web publication: https://www.biofrontera.com/en/investors/financial-reports publication date: 12. |
|
| March 31, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 31, 2021 |
Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp Exhibit 99.1 Biofrontera submits application for FDA approval of new BF-RhodoLED? XL lamp Leverkusen, Germany, March 31, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, today announced the submission for approval of a new, significantly larger red-light source for photodynamic therapy (PDT) to be used in combination w |
|
| March 31, 2021 |
Exhibit 99.1 News release Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results Leverkusen, Germany, March 31, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, will be releasing its financial results for the fiscal year 2020 on Monday, April 12, 2021. Conferenc |
|
| March 31, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 30, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 30, 2021 |
Biofrontera AG: Release of holders of qualifying holdings according to article 43 section 2 WpHG Exhibit 99.1 Biofrontera AG: Release of holders of qualifying holdings according to article 43 section 2 WpHG Announcements of holders of considerable holdings according to article 43 WpHG Leverkusen (pta042/29.03.2021/17:58) - Release according to § 43 WpHG Notification of Holdings By letter dated March 29, 2021, received on the same day, Biofrontera AG received the following notification pursuan |
|
| March 16, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 16, 2021 |
Exhibit 99.1 -CONVENIENCE TRANSLATION- Biofrontera Aktiengesellschaft Leverkusen 6 % convertible bond 2017/2022 DE000A2BPDE6. Adjustment of the conversion price The 6 % convertible bond 2017/2022 of Biofrontera AG (“Company”) is divided into bearer bonds with a nominal amount of EUR 100 each (“ 2017/2022 Bond”). Pursuant to the terms and conditions of the 2017/2022 Bonds (“2017/2022 Terms and Cond |
|
| March 4, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 4, 2021 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta039/03.03.2021/10:05) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkuse |
|
| March 3, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 3, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 3, 2021 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Leverkusen, Germany (pta016/03.03.2021/09:10) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, Germany 2. Reason for notification: Acquis |
|
| March 3, 2021 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Leverkusen, Germany (pta014/03.03.2021/09:05) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, Germany 2. Reason for notification: Acquis |
|
| March 1, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of princ |
|
| March 1, 2021 |
Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen (pta018/01.03.2021/10:00) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, Germany 2. Reason for |
|
| February 26, 2021 |
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million Exhibit 99.1 Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million Leverkusen, Germany, February 26, 2021? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (?Biofrontera? or the ?Company?), an international biopharmaceutical company, announces the closing of the capital increase resolved by the annual general meeting on May 28, 2020. The capi |
|
| February 26, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 26, 2021 |
Exhibit 1.1 UNDERWRITING AGREEMENT February 23, 2021 The Benchmark Company, LLC As Representative of the Underwriters named on Schedule 1 attached hereto 150 East 58th St, 17th Floor New York, NY 10155 Ladies and Gentlemen: The undersigned, Biofrontera AG, a German stock corporation (the ?Company?), hereby confirms its agreement (this ?Agreement?) with The Benchmark Company, LLC (hereinafter refer |
|
| February 26, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 25, 2021 |
Biofrontera AG: Biofrontera AG announces entry of capital increase into the commercial register EX-99.1 2 ex99-1.htm Exhibit 99.1 Biofrontera AG: Biofrontera AG announces entry of capital increase into the commercial register Business news for the stock market Leverkusen, Germany (pta050/25.02.2021/15:35) - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, announces the registration of the capital increa |
|
| February 25, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 25, 2021 |
Release according to article 40 para. 1 WpHG Exhibit 99.1 Release according to article 40 para. 1 WpHG Leverkusen (pta/25.02.2021/17:30) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, Germany 2. Reason for notification: Change of breakdown of voting rights 3. Deta |
|
| February 25, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 25, 2021 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/24.02.2021/17:30) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, |
|
| February 25, 2021 |
Release according to article 40 para. 1 WpHG Exhibit 99.1 Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/25.02.2021/14:00) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, Germany 2. Reason for notification: Acquisition / disposal of shares wi |
|
| February 25, 2021 |
Biofrontera AG: Total Voting Rights Announcement according to Article 41 of the WpHG Exhibit 99.1 Biofrontera AG: Total Voting Rights Announcement according to Article 41 of the WpHG Leverkusen, Germany (pta/24.02.2021/17:45) - Publication 1. Details of issuer Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Deutschland 2. Type of capital measure Other capital measure (Sec. 41 para. 1 WpHG) Date of status / date of effect: 24.02.2021 3. New total number of voting rights 56.7 |
|
| February 25, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 25, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) BIOFRONTERA AG (Name of Issuer) Ordinary Shares, with no par value, €1.00 nominal value per share (Title of Class of Securities) 09075G105** (CUSIP Number) Maruho Deutschland GmbH Hemmelrather Weg 201, Haus 2 51377 Leverkusen, Germany Telephone: +49(0)2 |
|
| February 25, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 25, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 25, 2021 |
BIOFRONTERA AG 1,334,002 American Depositary Shares Representing 2,668,004 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-236021 Prospectus Supplement (To prospectus dated February 18, 2020) BIOFRONTERA AG 1,334,002 American Depositary Shares Representing 2,668,004 Ordinary Shares We are offering 1,334,002 American Depositary Shares, or ADSs, each representing two ordinary shares, nominal value ?1.00 per share, of Biofrontera AG, a German stock corporation. Separa |
|
| February 24, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 24, 2021 |
Exhibit 99.1 Ad hoc Release Public disclosure of inside information according to article 17 MAR Biofrontera AG announces results of the capital increase resolved on May 28, 2020 - Gross proceeds of EUR 24.7 million Leverkusen, February 24, 2021 – On May 28, 2020, the annual general meeting of Biofrontera AG (hereinafter referred to as the “Company”) resolved to increase the share capital of the Co |
|
| February 24, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 24, 2021 |
NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES Exhibit 99.1 NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares Leverkusen, Germany, February 23, 2021 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today announced the pricing of a U.S. underwrit |
|
| February 24, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 24, 2021 |
Biofrontera submits study report of pharmacokinetics study to FDA Exhibit 99.1 Biofrontera submits study report of pharmacokinetics study to FDA Leverkusen, Germany, February 24, 2021 ? Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the ?Company?), an international biopharmaceutical company, announces the submission of an application to the U.S. Food and Drug Administration (FDA) to amend the product information to allow the simultaneous use of th |
|
| February 18, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 18, 2021 |
Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Managers’ transactions announcement according to article 19 MAR Leverkusen, Germany (pta031/18.02.2021/16:52) - Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr. Foguet Montserrat 2 Reason for the notification a) Position/status Other person discharging managerial responsibilities Senior Vice President, Regulatory Affair |
|
| February 18, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 18, 2021 |
Exhibit 99.1 Ad hoc Release Publication of inside information pursuant to Article 17 MAR Biofrontera AG announces subscription price of new shares from capital increase resolved on May 28, 2020 Leverkusen, Germany, February 18, 2021 – On May 28, 2020, the annual general meeting of Biofrontera AG (hereinafter referred to as the “Company”) resolved to increase the share capital of the Company by up |
|
| February 18, 2021 |
Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Managers? transactions announcement according to article 19 MAR Leverkusen, Germany (pta/18.02.2021/16:50) ? Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Prof. Dr. Hermann L?bbert 2 Reason for the notification a) Position/status Member of the managing body b) Initial notification 3 Details of the issuer, emission allowa |
|
| February 18, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant?s name / Translation of registrant?s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 11, 2021 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta028/11.02.2021/16:00) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkuse |
|
| February 11, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 8, 2021 |
Exhibit 99.1 “Not for distribution in the United States of America, Canada, Australia and Japan Biofrontera Aktiengesellschaft Leverkusen ISIN: DE0006046113 / WKN: 604611 Subscription offer The shareholders’ meeting of Biofrontera AG (hereinafter referred to as the “Company” or also the “Issuer”) of May 28, 2020, resolved to increase the share capital of the Company by up to EUR 8,969,870 by issui |
|
| February 8, 2021 |
License Agreement Biofrontera AG Maruho Co. Ltd. Exhibit 99.4 License Agreement Between Biofrontera AG and Maruho Co. Ltd. [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Table of Contents Preamble 3 1. Definitions 3 2. License 7 3. Considerations 8 4. Dossier 10 5. Obtaining and mai |
|
| February 8, 2021 | ||
| February 8, 2021 |
Exhibit 99.5 Service Agreement between Biofrontera Aktiengesellschaft, Hemmelrather Weg 201, 51377 Leverkusen, represented by the Supervisory Board, this represented by its Chairman, Dr. Ulrich Granzer, – hereinafter “Company”– and Ludwig Lutter, – hereinafter “Executive Board Member”– – Company and Member of the Management Board, hereinafter together “Parties”– Preamble Mr. Lutter was appointed a |
|
| February 8, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 8, 2021 |
Exhibit 99.2 BUSINESS DEVELOPMENTS Clinical updates Ameluz® for Treatment on Large or Multiple Surfaces In October 2020, we completed the clinical phase of the pharmacokinetics study in the United States of Ameluz®. The study had been ongoing since the beginning of 2020 with a temporary interruption due to the effect of restrictions put in place by various state and local governmental authorities |
|
| February 8, 2021 |
Fair Value as of June 30, 2020 Exhibit 99.1 Condensed interim consolidated financial statements as of June 30, 2020 Consolidated balance sheet as of June 30, 2020 Assets in EUR thousands June 30, 2020 December 31, 2019 Non-current assets Tangible assets 5,559 5,230 Intangible assets 20,065 22,848 Deferred taxes 7,475 7,794 Total non-current assets 33,099 35,872 Current assets Current financial assets Trade receivables 2,191 5,0 |
|
| February 8, 2021 |
§ 1 Wertpapierdarlehen, Übertragung der Wertpapiere Exhibit 99.3 Execution Version Die deutsche Fassung ist maßgeblich. Die englische Fassung ist eine Übersetzung ausschließlich zu Informationszwecken. The German version is binding. The English version is a convenience translation for information purposes only. Vertrag über ein Wertpapierdarlehen Share Loan Agreement zwischen between Maruho Deutschland GmbH, vertreten durch ihren einzelvertretungsb |
|
| February 8, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 8, 2021 |
Articles of Association of Biofrontera AG Exhibit 3.1 Certificate Pursuant to § 181 Para. 1 Sentence 2 of the German Stock Corporation Act (AktG) I hereby certify that the wording presented below of the Articles of Association of Biofrontera AG with its Head Office in Leverkusen contains the provisions of the Articles of Association amended by resolution of the Supervisory Board of 30 November 2020, and that the provisions of the Articles |
|
| February 8, 2021 |
(Subject to Completion) Dated February 8, 2021 Filed Pursuant to Rule 424(b)(3) Registration No. 333-236021 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement is not an offer to sell these securities and it is not soliciting an offer |
|
| February 4, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 4, 2021 |
Exhibit 99.1 Ad hoc Release Not for distribution in the United States, Canada, Australia and Japan Publication of an insider information pursuant to Art. 17 MAR Biofrontera AG specifies details of the capital increase resolved on May 28, 2020 - Subscription period begins February 08, 2021 Leverkusen, February 4, 2021 – The shareholders’ meeting of Biofrontera AG (hereinafter referred to as the “Co |
|
| February 2, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| February 2, 2021 |
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021 Exhibit 99.1 News release Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021 Leverkusen, Germany, February 2, 2020 – The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a change in the company’s Management Board. Effective March 1, 2021, Mr. Ludwig Lutte |
|
| January 8, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| January 8, 2021 |
Ad-hoc Release pursuant to Art. 17 MAR Exhibit 99.1 Ad-hoc Release pursuant to Art. 17 MAR Biofrontera announces preliminary revenue figures for the full year 2020 Leverkusen, Germany, January 08, 2021 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020. Biofrontera Group’s preliminary unaudited r |
|
| January 7, 2021 |
Ad-hoc Release pursuant to Art. 17 MAR Exhibit 99.1 Ad-hoc Release pursuant to Art. 17 MAR Cologne Higher Regional Court grants approval of capital increase Leverkusen, Germany, January 07, 2021 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the Cologne Higher Regional Court has granted the release of the capital increase resolved by the Annual |
|
| January 7, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| January 6, 2021 |
Exhibit 99.1 Corporate calendar 2021 Please note Biofrontera’s tentative financial reporting dates as follows: Event Publication date Annual report 2020 April 2021 First quarter 2021 interim statement May 2021 Half-year report 2021 August 2021 Third quarter 2021 interim statement November 2021 Annual general meeting 2021 June 2021 Analyst conference 2021 November 2021 Please visit our corporate we |
|
| January 6, 2021 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| December 28, 2020 |
As Filed With the Securities and Exchange Commission on December 23, 2020 Registration No. |
|
| December 22, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| December 22, 2020 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/22.12.2020/17:00) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, |
|
| December 7, 2020 |
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz Exhibit 99.1 Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia Leverkusen, Germany, December 7, 2020 – Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö, Sweden, today signed an exclusive license and supply agreement for the marketing of both Am |
|
| December 7, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* Biofrontera AG (Name of Issuer) Ordinary Shares, nominal value €1.00 per share (including Ordinary Shares represented by American Depository Shares (ADSs) at a ratio of two Ordinary Shares per ADS) (Title of Class of Securities) 09075G105 ** (CUSIP Numb |
|
| November 27, 2020 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/26.11.2020/15:00) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, |
|
| November 27, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 23, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 23, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 23, 2020 |
Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Managers’ transactions announcement according to article 19 MAR Leverkusen, Germany (pta/23.11.2020/16:50) – Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Prof. Dr. Hermann Lübbert 2 Reason for the notification a) Position/status Member of th |
|
| November 23, 2020 |
Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Managers’ transactions announcement according to article 19 MAR Leverkusen, Germany (pta/23.11.2020/16:51) – Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr. Montserrat Fouget Roca 2 Reason for the notification a) Position/status Other perso |
|
| November 23, 2020 |
Biofrontera AG: Total Voting Rights Announcement according to Article 41 of the WpHG Exhibit 99.1 Biofrontera AG: Total Voting Rights Announcement according to Article 41 of the WpHG Total voting rights according to article 41 WpHG Leverkusen, Germany (pta/23.11.2020/11:15) 1. Details of issuer Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Deutschland 2. Type of capital measure Other capital measure (Sec. 41 para. 1 WpHG) Date of status / date of effect: 23.11.2020 3. New |
|
| November 23, 2020 |
Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Managers’ transactions announcement according to article 19 MAR Leverkusen, Germany (pta/23.11.2020/16:52) – Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Thomas Schaffer 2 Reason for the notification a) Position/status Member of the managing |
|
| November 23, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 23, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 18, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 18, 2020 |
Exhibit 99.1 - CONVENIENCE TRANSLATION – Biofrontera AG Leverkusen Notification of mandatory conversion pursuant to Section 8 (2) of the terms and conditions of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021 (“Terms and Conditions of the Bonds”) (ISIN DE000A3E454 8 / WKN A3E454) Biofrontera AG (“Issuer”) has issued the 1.00% qualified subordinated mandatory convertible bond |
|
| November 12, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 12, 2020 |
Exhibit 99.2 QUARTERLY REPORT For the third quarter ended September 30,2020 Dear shareholders, The coronavirus pandemic continues to be a tremendous challenge for us all. The continuing COVID-19 situation is disrupting economic activity and continues to dictate the behavior of people, businesses and governments around the world on a daily basis. Since mid-March, Biofrontera has also been affected |
|
| November 12, 2020 |
Biofrontera reports third quarter and first nine months 2020 results Exhibit 99.1 Biofrontera reports third quarter and first nine months 2020 results Leverkusen, Germany, November 11, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its results for the third quarter ended September 30, 2020. In addition, the Company provided an overview of the current business performan |
|
| November 12, 2020 |
Ad-hoc Release pursuant to Art. 17 MAR Exhibit 99.1 Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds Leverkusen, Germany, November 12, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00% qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E45 |
|
| November 12, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 2, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pr |
|
| November 2, 2020 |
Exhibit 99.1 News release Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results Leverkusen, Germany, November 2, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its unaudited financial results for the third quarter ended September 30, 2020 on Wedne |
|
| October 30, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| October 30, 2020 |
Biofrontera AG: Total Voting Rights Announcement according to Article 41 of the WpHG Exhibit 99.1 Biofrontera AG: Total Voting Rights Announcement according to Article 41 of the WpHG Leverkusen, Germany (pta/30.10.2020/10:05) – Publication 1. Details of issuer Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Deutschland 2. Type of capital measure Conditional capital increase (Sec. 41 para. 2 WpHG) Date of status / date of effect: 30.10.2020 3. New total number of voting righ |
|
| October 14, 2020 |
Exhibit 99.1 News release Biofrontera AG receives statement of reasons from the Federal Court of Justice for overturning the ruling of the Cologne Higher Regional Court Leverkusen, Germany, October 14, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on September 22, 2020, that in a ruling from September |
|
| October 14, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| October 9, 2020 |
Ad-hoc Release pursuant to Art. 17 MAR Exhibit 99.1 Ad-hoc Release pursuant to Art. 17 MAR Biofrontera reports preliminary unaudited sales revenue for the third quarter of 2020 Leverkusen, Germany, October 09, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2020. The Biofronte |
|
| October 9, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| October 8, 2020 |
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study Exhibit 99.1 News release Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study Leverkusen, Germany, October 8, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the completion of the clinical phase (last subject last visit) of the pharmacokinetics study (PK study) to test the saf |
|
| October 8, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of pri |
|
| September 23, 2020 |
Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court Exhibit 99.1 News release Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court Leverkusen, Germany, September 22, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in ruling on September 22, 2020, the German Federal Supreme Court overturned a decision by the C |
|
| September 23, 2020 |
SC 13D/A 1 ea127204-sc13da11abcbio.htm AMENDMENT NO. 11 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Biofrontera AG (Name of Issuer) Ordinary Shares, nominal value €1.00 per share (including Ordinary Shares represented by American Depository Shares (ADSs) at a ratio of two Ordinary |
|
| September 23, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of p |
|
| September 21, 2020 |
Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Managers’ transactions announcement according to article 19 MAR Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Leverkusen, Germany (pta027/21.09.2020/16:00) – Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Thomas Schaffer 2 Reason for the notification a) Position/status Member of the manag |
|
| September 21, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of p |
|
| September 21, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of p |
|
| September 21, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of p |
|
| September 21, 2020 |
Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Managers’ transactions announcement according to article 19 MAR Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Leverkusen, Germany (pta025/21.09.2020/16:00) – Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr. Montserrat Foguet Roca 2 Reason for the notification a) Position/status Other pe |
|
| September 21, 2020 |
Managers’ transactions announcement according to article 19 MAR Exhibit 99.1 Managers’ transactions announcement according to article 19 MAR Biofrontera AG: Managers’ transactions announcement according to article 19 MAR Leverkusen (pta023/21.09.2020/16:00) – Announcement 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Prof. Dr. Hermann Lübbert 2 Reason for the notification a) Position/status Member of the mana |
|
| September 11, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of p |
|
| September 11, 2020 |
Exhibit 99.1 Ad hoc release Ad-hoc Release pursuant to Art. 17 MAR Biofrontera AG plans mediation to resolve (legal) disputes Leverkusen, Germany, September 11, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical company, today has reached a mutual agreement with Mr. Wilhelm K.T. Zours and Deutsche Balat |
|
| September 9, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of p |
|
| September 9, 2020 |
Biofrontera AG to participate in two upcoming conferences EX-99.1 2 ex99-1.htm Exhibit 99.1 Biofrontera AG to participate in two upcoming conferences Leverkusen, Germany, September 9, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating virtually in two upcoming conferences. On September 17, 2020, members of Biofrontera’s management team will attend the 2020 |
|
| August 28, 2020 |
Exhibit 99-1 Biofrontera Aktiengesellschaft Leverkusen 6% Convertible Bond 2017/2022 DE000A2BPDE6 Announcement of the adjustment of the conversion price The 6% convertible bond 2017/2022 of Biofrontera AG (“Company”) is divided into convertible bearer bonds (“Bond 2017/2022”) with a nominal value of EUR 100 each. |
|
| August 28, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Biofrontera AG (Name of Issuer) Ordinary Shares, nominal value €1.00 per share (including Ordinary Shares represented by American Depository Shares (ADSs) at a ratio of two Ordinary Shares per ADS) (Title of Class of Securities) 09075G105 ** (CUSIP Numb |
|
| August 27, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 27, 2020 |
Biofrontera report results for the first six months of 2020 Exhibit 99.1 News release Biofrontera report results for the first six months of 2020 Leverkusen, Germany, August 26, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its results for the first six months ended June 30, 2020. In addition, the Company provided an overview of the current business performan |
|
| August 27, 2020 |
Exhibit 99.2 Table of contents Highlights for the first six months ended June 30, 2020 3 Key figures in accordance with IFRS 3 Investor Relations 5 Interim group management report for the first half of the 2020 financial year 9 Group structure 9 Business model 9 Group strategy 9 Products 10 Sales and markets 12 Research and development projects 13 Patent development 14 Employees 15 Management repo |
|
| August 25, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 25, 2020 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/24.08.2020/17:01) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, |
|
| August 25, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 25, 2020 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/24.08.2020/17:00) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, |
|
| August 21, 2020 |
Exhibit 99.1 News release Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021 Leverkusen, Germany, August 20, 2020 – On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified subordinated mandatory convertible bond 2020/2021 with gross proceeds of EUR 7.9 million. W |
|
| August 21, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 19, 2020 |
Current Report of Foreign Issuer - 6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen German |
|
| August 19, 2020 |
Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38396 BIOFRONTERA AG (Registrant’s name / Translation of registrant’s name into English) Hemmelrather Weg 201, D-51377 Leverkusen Germany (Address of prin |
|
| August 19, 2020 |
Exhibit 99.1 News release Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results Leverkusen, Germany, August 19, 2020 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2020 on Wednesday, Au |
|
| August 19, 2020 |
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Exhibit 99.1 Biofrontera AG: Release according to Article 40, Section 1 of the WpHG Release according to article 40 para. 1 WpHG Leverkusen, Germany (pta/18.08.2020/17:05) - Release of Voting Rights Announcement Voting Rights Announcement 1. Details of issuer: Name: Biofrontera AG Legal Entity Identifier (LEI): 391200D6GFSVFGFQTL13 Street: Hemmelrather Weg 201 Postal code: 51377 City: Leverkusen, |
